Clinical Trials

Major advances in medicine have been made by extending the biological discoveries in the laboratories to clinical settings and treating patients. This is the basic methodology that KRF is planning to use in finding better treatments for keloid disorder. This very important methodology will bring us unprecedented opportunities to change the practice of medicine, the obstacles facing us in treatment of patients with keloid. Medical research is a continuum that spans diverse realms of laboratory research and several kinds of clinical research. Clinical research is a crucial element and an essential step in this endeavor.

What is clinical research?

Clinical research refers to research conducted with human beings, including studies of specimens collected from patients who have keloid. It encompasses some laboratory research on the mechanisms of human disease, translational research (in which laboratory and clinical activities are closely aligned), clinical trials of preventive and therapeutic strategies, epidemiology, behavioral research, and health services and outcomes research.

Because it covers so many topics, clinical research the skills and expertise of many kinds of investigators, including physician scientists, public health, nursing and various laboratory sciences, are needed. Other professionals such as computer programmers, bio-engineers, and technicians are also essential for clinical research. Clinical research is conducted at a variety of sites and by a variety of entities. Academic Health Centers (AHCs), government labs and clinics, community hospitals, State health organizations, and managed care and pharmaceutical industry sites are all active participants in the Nation's clinical research enterprise. The success of clinical research depends on funding from both Federal and private sector sources. Much of the research funds are funneled to cancer research, and research in infectious diseases like HIV. With proper funding, KRF will be able to foster much needed research in keloid and pave the way for better understanding this disease and testing innovative treatments.

Clinical research has changed the face of modern medicine. At the end of World War II, physicians had little ability to effectively treat or prevent any of the deadliest diseases. Most of what we know as modem medicine, which we enjoy today were still unknown: antibiotics, vaccines for polio and several other severe infections, most hormone replacements and steroid therapy, effective drug therapies for cancer and psychotic illnesses, testing for genetic disorders, coronary bypass surgery, transplanted organs, and artificial joints. These and other successes have encouraged public enthusiasm for research and belief in the potency of modem medicine. Progress in cardio vascular disease, cancer, diabetes, infectious diseases, etc., would not have been possible without clinical research and funding that has supported the scientific discoveries. With similar enthusiasm, we can advance our understanding and treatments for keloid.

We do not even have statistics about keloid and do not know how prevalent this disease is. KRF intends to also develop a methodology to capture this data. We need to know how many people are suffering from this disease, so that we can effectively lobby for public and Federal research funds.

Medical research has visibly transformed the practice of medicine over the past fifty-sixty years, but even greater benefits may be possible in the future, if we are positioned to capitalize on the many profound developments that have recently occurred in fundamental science --- especially in genetics, structural biology, molecular and cell biology, computer science, and imaging technologies and applying all that to a keloid disorder, a disease that has been simply neglected by the research community.

LATEST NEWS

    Notice of 501 (C)(3) Status:

    (February 1, 2017) Keloid Research Foundation has been determined by the US Internal Revenue Service (IRS) to be exempt from federal income tax under Internal Revenue Code (IRC) Section 501(C)(3). Donors can deduct contributions they make to KRF under IRC Section 170. Click here to view the 501(C)(3) Exemption Document.

    Journal of Keloid Research:

    (December 3, 2016)KRF is proud to announce establishment of Keloid Research, an open access scientific publication of the Keloid Research Foundation. Until now, keloid manuscripts have been published in a variety of journals. Our goal is to create a centralized publishing platform for all researchers who are passionate about this disorder, so that relevant clinical and laboratory research can be published in one place and under one umbrella. The journal is aiming to provide an international forum for the publication of original work, describing basic science, translational and clinical investigations in keloid disorder.

    Keloid Staging System:

    (August 19, 2016) In his most recent publication, "Neck Keloids: evaluation of risk factors and recommendation for keloid staging system" Dr. Tirgan has designed a staging system that allows for proper categorization and grouping of keloid patients into various stages.

    To assess each keloid patient properly, to better understand the natural history of this disorder, and to be able to compare future keloid study results among various patients groups, we clearly need a staging system that can allow us to describe the severity keloid disorder based on the size, location and/or extent of the keloidal lesions; as well as history of surgery or radiation therapy, and perhaps other factors that are currently unknown to us. Please click HERE to read more.

    International Keloid Symposium:

    (March 11, 2016) KRF is proudly announcing that the 1st ever will be held on September 8 - 9, 2016 at Rockefeller University in New York. KRF Extends its gratitude to Rockefeller University for hosting this meeting and its support for keloid research. Click on the image below to be directed to the symposium website.

  • March 11, 2016
  • Dr. Patricia Danielsen has joined the board of Directors of KRF:

    KRF is pleased to announce that Dr. Patricia Danielsen has joined the board of directors of KRF. Dr. Danielsen is a dermatologist at the Department of Dermatology and Copenhagen Wound Healing Center, Copenhagen University Hospital, Denmark. She has a PhD in wound healing and scar treatment science and a continuing academic career with a special focus on keloid scar disease. We welcome Dr. Danielsen and look forward to working with her in strengthening KRF.

  • November 1, 2015
  • KRF presentations at ETRS 2015 meeting:
  • Dr. Michael H. Tirgan was invited and gave two talks on Keloid Disorder at the Keloid Satellite Symposium during the 7th Joint Meeting of the European Tissue Repair Society & the Wound Healing Society that was held 21-23 October 2015 in Copenhagen, Denmark.

  • August 15, 2015
  • Atlas of Ear Keloids:
  • KRF is pleased to announce publication of it first sponsored book, Atlas of Ear Keloids. This full color atlas, authored by Dr. Michael Tirgan, provides an insight into natural history of ear keloids. With over 130 full color images of ear keloids, Dr. Tirgan provides a solid proof that surgery is not a treatment for keloid disorder.

    Atlas of Ear Keloids by Dr. Michael H. Tirgan

  • August 1, 2015
  • KRF presenting at ETRS 2015 meeting:
  • KRF was able to arrange for a scientific session dedicated to keloid research the 7th Joint Meeting of the European Tissue Repair Society & the Wound Healing Society that will be held 21-23 October 2015 in Copenhagen, Denmark. This will be the very first dedicated scientific session that KRF has been able to organize.

  • November 11, 2011
  • KRF Formally Registered in New York State
  • KRF is pleased to announce that its Certificate of Incorporation was accepted and filled by the State of New York. KRF is now able to conduct fund raising activities to support conduct of much needed research in the field of Keloid.
  • October 18, 2011
  • Grant Approval from Rockefeller University
  • KRF is pleased to announce that Dr. Tirgan's proposal to study "Pathogenesis of Keloid" was approved by the Rockefeller University Center for Clinical and Translational Sciences. (RUCCTS Grant # 2UL1RR024143 from the National Center for Research Resources, National Institutes of Health). We thank Rockefeller University for extending support to our fight against keloid disorder. www.KeloidTissueBank.com is the official website of the main study.
  • October 14, 2011
  • Dr. James N. Musyoka, joins KRF
  • KRF is pleased to announce that Dr. Musyoka has joined KRF. Dr. Musyoka has just completed his PhD with focus on would healing and keloid research and has previously conducted laboratory research in this area. We welcome Dr. Musyoka as a new member of KRF.
  • August 4, 2011
  • Dr. Djoned Sananto joins KRF
  • KRF is pleased to announce that Dr. Sananto, Head of Plastic Surgery Department at Haji General Hospital in Indonesia, has joined KRF. Dr. Sananto has strong interest in keloid disorder, actively treats patients with keloids, has previously conducted laboratory research in keloid and published the study results. We welcome Dr. Sananto as a new member of KRF.
  • July 28, 2011
  • Advanced Pathology Laboratory Partners with KRF
  • KRF is pleased to announce that the Director of Advanced Pathology Laboratory, Dr. Ali Daneshvar, has made a long term commitment to serve as the Tissue Bank arm of KRF. Advanced Pathology Laboratory is a CLIA certified full service pathology laboratory, located in Northfiled, New Jersey.
  • July 21, 2011
  • KRF Appoints General Counsel
  • KRF is pleased to announce appointment of its General Counsel. Attorney Ronald R. Benjamin of Binghamton, New York has been appointed General Counsel for Keloid Research Foundation. He will oversee all legal matters that concern operations of KRF. Mr. Benjamin has been practicing public interest law since 1979.
  • July 18, 2011
  • Certificate of Incorporation for KRF
  • The Certificate of Incorporation for KRF was completed by three initial board members, Michael Tirgan, MD acting as the Medical Officer, Nadereh Nouhi acting as the Business Manager and Alexander Duggan acting as the Patient Advocate and Liaison.